On-line version ISSN 1414-431X
Braz J Med Biol Res vol. 31 no. 1 Ribeirão Preto Jan. 1998
Braz J Med Biol Res, January 1998, Volume 31(1) 149-155
M. Barral-Netto1,2, C. Brodskyn2, E.M. Carvalho2 and A. Barral1,2
1Centro de Pesquisas Gonçalo Moniz, FIOCRUZ, Salvador, BA, Brasil
2Serviço de Imunologia, Hospital Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, BA, Brasil
The cell-mediated immune response is critical in the resistance to and recovery from leishmaniasis. Cytokines are central elements in mounting an immune response and have received a great deal of attention in both human and experimental leishmaniasis. IFN-g is responsible for macrophage activation leading to leishmanicidal mechanisms. Understanding the balance of cytokines that lead to enhanced production of or synergize with IFN-g, and those cytokines that counterbalance its effects is fundamental for developing rational immunotherapeutic or immunoprophylactic approaches to leishmaniasis. Here we focus on the cytokine balance in human leishmaniasis, particularly IL-10 as an IFN-g opposing cytokine, and IL-12 as an IFN-g inducer. The effects of these cytokines were evaluated in terms of several parameters of the human immune response. IL-10 reduced lymphocyte proliferation, IFN-g production and cytotoxic activity of responsive human peripheral blood mononuclear cells. Neutralization of IL-10 led to partial restoration of lymphoproliferation, IFN-g production and cytotoxic activity in unresponsive visceral leishmaniasis patients. IL-12 also restored the responses of peripheral blood mononuclear cells from visceral leishmaniasis patients. The responses obtained with IL-12 are higher than those obtained with anti-IL-10, even when anti-IL-10 is combined with anti-IL-4.
Key words: cytokines, human leishmaniasis, immunoregulation, IL-12, IL-10
Leishmaniasis is endemic in many parts of the world, with a prevalence of 12 million individuals (1). The clinical presentations of leishmaniasis are critically influenced by the host immune response. Cure or disease progression has been related to the predominance of a Th1 type of immune response (IFN-g being the prototypic cytokine) or to a Th2 type of response (with an important production of IL-10), respectively. IFN-g is responsible for macrophage activation leading to leishmanicidal mechanisms, whereas IL-10 leads to macrophage deactivation (2). Effort is focused on the understanding of the early events that may influence the development of a Th1 or a Th2 type of response, and the interplay of several cytokines in order to determine their relative role in mounting or impeding an effective host protective response.
We will divide the present review into three areas: 1) pathogenesis, and clinical and immunological aspects of human leishmaniasis; 2) IL-12 and host protection, and 3) IL-10 and disease progression.
Pathogenesis, and clinical and immunological aspects of human leishmaniasis
Since most studies in the cytokine literature deal with experimental Leishmania infections, we think it is appropriate to briefly review some aspects of the human disease in order to better appreciate the findings in human leishmaniasis.
Following inoculation into the skin, the flagellated promastigote penetrates into the macrophage, transforms into amastigotes and multiplies. Leishmanicidal activity is probably due to the increased capacity of the macrophages to produce toxic oxygen and nitrogen radicals in response to IFN-g. Nitric oxide production and Leishmania killing by human macrophages through the ligation of Fc e RII/CD23 have been shown (3). A summary of the role of IFN-g in human leishmaniasis is presented in Table 1.
The course of leishmaniasis has been associated with different cytokine patterns, which parallel cure or non-cure of disease in mice. The polarized responses do not change easily in vivo after 2 to 3 weeks of Leishmania infection in mice. A change from a Th1 to a Th2 population in Leishmania-specific cells has been obtained by the use of IL-4 in vitro (4) or in vivo (5). The combination of anti-IL-4 or IL-12 with antimony (6,7) promoted a change from a Th2 to a Th1 type of response in L. major-infected animals.
Th1 x Th2 dichotomy is probably influenced by cytokine patterns present during the very early stages of Leishmania survival inside the macrophage. Upon its entry into the human macrophage Leishmania induces contrasting signals. It induces the production of TNF-a, which leads to macrophage activation, or to the production of TGF-ß or IL-10, linked to macrophage deactivation and inhibition of IFN-g (8,9). IFN-g produced by NK cells, which may depend on the production of IL-12, is also implicated in initial Th1 development (10). Initial survival of Leishmania inside the macrophage probably depends on which of these or similar cytokines predominate in the microenvironment of infection. A recent observation suggests the participation of different isolates of Leishmania aethiopica in inducing the production of IFN-g or IL-10 by peripheral blood mononuclear cells (PBMC) from patients (11). Leishmania penetration also induces the production of several other products by macrophages, which may influence parasite survival (12-15).
The clinical manifestations of tegumentary leishmaniasis include the self-healing cutaneous disease (CL) and the destructive and hyper-responsive mucosal form (ML). More rarely the anergic form of diffuse cutaneous leishmaniasis (DCL) is observed. The most frequent aspect observed in CL cases is an ulcer with elevated borders and a sharp crater. CL patients exhibit anti-Leishmania cell-mediated immunity (CMI). Mucosal involvement, with disfiguring destruction of palate, uvula, pharynx, gums and upper lip, occurs in approximately 3% of patients infected by L. braziliensis. ML is considered to be the hyper-responsive pole of the disease due to the potent anti-Leishmania CMI responses observed in these patients. CL or ML patients may not exhibit a positive anti-leishmanial response (delayed-type hypersensitivity (DTH) and lymphocyte in vitro proliferation) before two to three months of infection. With disease progression, ML patients tend to develop larger intradermal skin test reactions, and their lymphocytes exhibit higher proliferative responses and production of IFN-g than cells from CL patients. The initial lesion of DCL resembles those of CL without ulceration. The lesions present predominantly as erythematous papules or nodules. DCL occurs in the absence of anti-parasite CMI. Patients with DCL have a complete anergy to leishmanial antigen. DTH is negative and their lymphocytes do not respond to leishmanial antigen either by proliferation or by lymphokine production. DCL patients present an antigen-specific immunosuppression, mounting normal responses to other antigens. The characteristics of the different forms of human tegumentary leishmaniasis have been recently reviewed (1,16).
The actual role of the cytokine network in human leishmaniasis needs to be better defined. A preferential participation of Th1 or Th2 cell types within human cutaneous lesions is not completely clear as evaluated by cytokine gene expression in CL or DCL (17-23), or in visceral leishmaniasis (VL) patients (24-26).
IL-12 and host protection
IL-12 has received a great deal of attention in leishmaniasis (Table 2). IL-12 is produced following in vivo infection of mice by Leishmania (27,28), and is important to control Th2 expansion and promote the predominance of a Th1 type of response (28-30). In vitro, however, the parasite is able to inhibit IL-12 production by the infected macrophages (31,32). Treatment of susceptible animals with IL-12 renders them resistant (30,33-35), and has also been used as an effective adjuvant for a killed vaccine for L. major (36).
In human leishmaniasis, expression of IL-12 mRNA has been shown in active CL cases (21). In VL patients, IL-12 enhances Th1 responses (37), restoring lymphocyte proliferative responses, IFN-g production and cytotoxic responses, as shown in Figure 1 (38). IL-12 also decreases spontaneous or Ag-induced PBMC apoptosis in VL patients (Figure 1).
IL-12 used in combination with Leishmania antigen restores proliferation of PBMC from VL patients more strongly than the use of anti-IL-4 or anti-IL-10 monoclonal antibodies, or even of both monoclonals combined (Figure 2).
Figure 1 - Effect of IL-12 on the responsiveness of PBMC from visceral leishmaniasis (VL) patients. Panel A shows that the addition of IL-12 + Leishmania antigen (black bars) reversed both lymphocyte proliferation (proliferation reported as stimulation index = E/C) and cytotoxic responses against K562 tumor target cells (cytotoxicity reported as lytic units (LU) per million PBMC), as compared to cells receiving Leishmania antigen alone (hatched bars). In Panel B the addition of IL-12 + Leishmania antigen (black bars) partially reversed the rate of antigen-induced (hatched bars) PBMC apoptosis in VL patients (results are reported as percentage of apoptotic cells as evidenced by propidium iodide staining and FACS analyses). Bars represent the mean ± SD of at least six determinations.
IL-10 and disease progression
The prominent role of IL-4 as the leading Th2 cytokine in murine leishmaniasis was not consistently shown in human leishmaniasis. IL-10 seems to represent the main macrophage-"deactivating" cytokine in opposition to IFN-g (Figure 3), being present in many different clinical presentations of human leishmaniasis (Table 3). IL-10, however, is not a strict Th2 cytokine, since it can be produced by macrophages, B cells and mast cells, besides Th2 cells.
IL-10 blunts several immunological responses mediated by lymphocytes from tegumentary leishmaniasis patients (Figure 4). IL-10 is responsible for decreased antigen presentation by macrophages and inhibition of cytokine production by Th1 or other cells, including NK cells (39-45), and these effects may be responsible for its inhibitory action in leishmaniasis.
A predominance of Th1 cytokines in CL, with small amounts of IL-10 in DCL, has been shown in Brazilian patients (19). A comparison of cytokine mRNA expression in intralesional cells obtained from acute (less than 2 months) or chronic CL lesions was recently performed, with variable amounts of IL-10 detected in all cases. Chronic lesions exhibited higher expression of IL-10 mRNA than recent ones (22). In order to address the relationship between clinical status and cytokine pattern, we have performed a study analyzing 6 patients with DCL who exhibited transient clinical improvement following therapy. There was, as expected, a preferential differentiation of a Th2 type of response during the active phase of DCL, characterized by a high expression of IL-4 and IL-10 in most patients, with no expression of IFN-g. The comparison of the DCL cytokine pattern with those of CL patients shows a clear difference in IFN-g expression, which is expressed in CL but not in DCL (23). After specific therapy, the cytokine pattern observed in DCL patients changed dramatically. An important expression of IFN-g mRNA and reduced amounts of IL-10 mRNA were observed (23).
Since lymphadenopathy is the earliest clinical stage of human leishmaniasis available for investigation, we have determined the cytokine profile for IL-2, IL-4, IL-10, IL-12, TGF-ß and IFN-g in lymph node cells from 10 patients with early cutaneous leishmanial infection by RT-PCR. At the time of diagnosis, none of the patients had a skin lesion but all had Leishmania cultivated from the lymph node. mRNA for IL-4 and IFN-g were observed in several cases, but none showed a signal for IL-10. On the other hand, IL-10 mRNA has been demonstrated in lymph nodes from VL patients (26).
Studies in human leishmaniasis confirm the relevant roles of IFN-g and IL-12 as the major cytokines involved in host protection, whereas IL-10 takes the place as the leading cytokine responsible for parasite survival and disease progression. Other less explored cytokines may also prove important in immunoregulation in human leishmaniasis. Future strategies for vaccination or immunotherapy must take into account such findings, which do not always parallel mouse studies.
1. Barral-Netto M, Machado P, Bittencourt AL & Barral A (1997). Recent advances in pathophysiology and treatment of human cutaneous leishmaniasis. Current Opinion in Dermatology, 4: 51-58. [ Links ]
2. Carvalho EM, Barral-Netto M, Barral A, Brodskyn C & Bacellar O (1994). Immunoregulation in leishmaniasis. Ciência e Cultura, 46: 441-445. [ Links ]
3. Vouldoukis I, Riveros-Moreno V, Dugas B, Ouaaz F, Becherel P, Debre P, Moncada S & Mossalayi MD (1995). The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 antigen. Proceedings of the National Academy of Sciences, USA, 92: 7804-7808. [ Links ]
4. Mocci S & Coffman RL (1995). Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4. Journal of Immunology, 154: 3779-3787. [ Links ]
5. Coffman RL, Correa-Oliveira R & Mocci S (1995). Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis. Ciba Foundation Symposium, 195: 20-25. [ Links ]
6. Nabors GS & Farrell JP (1994). Depletion of IL-4 in BALB/c mice with established L. major infections increases the efficacy of antimony therapy and promotes Th1 like responses. Infection and Immunity, 62: 5498-5504. [ Links ]
7. Nabors GS, Afonso LCC, Farrell JP & Scott P (1995). Switch from a type 2 to a type 1 helper cell response and cure of established L. major infection in mice by combined therapy with IL-12 and Petostam. Proceedings of the National Academy of Sciences, USA, 92: 3142-3146. [ Links ]
8. Barral A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, Bittencourt AL, Reed SG, Carvalho EM & Barral-Netto M (1995). Transforming growth factor in human cutaneous leishmaniasis. American Journal of Pathology, 147: 947-953. [ Links ]
9. Barral-Netto M, Badaro R, Barral A, Almeida RP, Santos S, Badaro F, Pedral-Sampaio D, Carvalho EM, Falcoff E & Falcoff R (1991). Tumor necrosis factor (cachectin) in human visceral leishmaniasis. Journal of Infectious Diseases, 163: 853-857. [ Links ]
10. Scharton-Kersten T & Scott P (1995). The role of the innate immune response in Th1 cell development following L. major infection. Journal of Leukocyte Biology, 57: 515-522. [ Links ]
11. Akuffo H, Maasho K, Blostedt M, Hojeberg B, Britton S & Bakhiet M (1997). Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. Journal of Infectious Diseases, 175: 737-741. [ Links ]
12. Goebeler M, Roth J, Kunz M & Sorg C (1993). Expression of intercellular adhesion molecule-1 by murine macrophages is up-regulated during differentiation and inflammatory activation. Immunobiology, 188: 159-171. [ Links ]
13. Badolato R, Sacks DL, Savoia D & Musso T (1996). Leishmania major: infection of human monocytes induces expression of IL-8 and MCAF. Experimental Parasitology, 82: 21-26. [ Links ]
14. Milano S, Arcoleo F, Dieli M, D'Agostino R, De Nucci G, D'Agostino P & Cillari E (1996). Ex vivo evidence for PGE2 and LTB4 involvement in cutaneous leishmaniasis: relation with infection status and cytokine production. Parasitology, 112: 13-19. [ Links ]
15. Racoosin EL & Beverley SM (1997). Leishmania major: promastigotes induce expression of a subset of chemokine genes in murine macrophages. Experimental Parasitology, 85: 283-295. [ Links ]
16. Barral-Netto M, Machado P & Barral A (1995). Human cutaneous leishmaniasis. Recent advances in physiopathology and treatment. European Journal of Dermatology, 5: 104-113. [ Links ]
17. Frakenburg S, Kofsky Y & Gross A (1993). In vitro secretion of cytokines by human mononuclear cells of individuals during and after cutaneous leishmaniasis infection. Parasite Immunology, 15: 509-512. [ Links ]
18. Kemp M, Hey AS, Kurtzhals JA, Christensen CB, Gaafar A, Mustafa MD, Kordofani AA, Ismail A, Kharazmi A & Theander TG (1994). Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clinical and Experimental Immunology, 96: 410-415. [ Links ]
19. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceiçào-Silva F & Modlin RL (1993). Cytokine patterns in the pathogenesis of human leishmaniasis. Journal of Clinical Investigation, 91: 1390-1395. [ Links ]
20. Cáceres-Dittmar G, Tapia FJ, Sánchez MA, Yamamura M, Uyemura K, Modlin RL, Bloom BR & Convit J (1993). Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clinical and Experimental Immunology, 91: 500-505. [ Links ]
21. Melby PC, Andrade-Narvaez FJ, Darnell BJ & Valencia-Pacheco G (1996). In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. FEMS Immunology and Medical Microbiology, 15: 101-107. [ Links ]
22. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV & Palomo-Cetina A (1994). Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infection and Immunity, 62: 837-842. [ Links ]
23. Bomfim G, Nascimento C, Costa J, Carvalho EM, Barral-Netto M & Barral A (1996). Variation of cytokine patterns related to therapeutic response in diffuse cutaneous leishmaniasis. Experimental Parasitology, 88: 188-194. [ Links ]
24. Karp CL, El-Safi SH, Wynn TA, Satti MMH, Kordofani AM, Hashim FA, Hag-Ali M, Neva FA, Nutman TB & Sacks DL (1993). In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. Journal of Clinical Investigation, 91: 1644-1648. [ Links ]
25. Cillari E, Vitale G, Arcoleo F, D'Agostino P, Mocciaro C, Gambino G, Malta R, Stassi G, Giordano C & Milano S (1995). In vivo and in vitro cytokine profiles and mononuclear subsets in Sicilian patients with active visceral leishmaniasis. Cytokine, 7: 740-745. [ Links ]
26. Ghalib HW, Piuvezam MR, Skeiky YAW, Siddig M, Hashim FA, El-Hassan AM, Russo DM & Reed SG (1993). Interleukin 10 production correlates with pathology in human Leishmania donovani infections. Journal of Clinical Investigation, 92: 324-329. [ Links ]
27. Sypek JP, Jacobson S, Vorys A & Wyler DJ (1993). Comparison of gamma interferon, tumor necrosis factor, and direct cell contact in activation of antimycobacterial defense in murine macrophages. Infection and Immunity, 61: 3901-3906. [ Links ]
28. Heinzel FP, Rerko RM, Ahmed F & Pearlman E (1995). Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. Journal of Immunology, 155: 730-739. [ Links ]
29. Scharton-Kersten T, Afonso LCC, Wysocka M, Trinchieri G & Scott P (1995). IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. Journal of Immunology, 154: 5320-5330. [ Links ]
30. Murray HW, Hariprashad J & Coffman RL (1997). Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. Journal of Experimental Medicine, 195: 867-874. [ Links ]
31. Reiner SL, Zheng S, Wang Z-E, Stowring L & Locksley RM (1994). Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. Journal of Experimental Medicine, 179: 447-456. [ Links ]
32. Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R & Sacks DL (1996). Leishmania promastigotes selectively inhibit interleukin-12 induction in bone marrow-derived macrophages from susceptible and resistant mice. Journal of Experimental Medicine, 183: 515-526. [ Links ]
33. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE & Gately MK (1993). Recombinant interleukin 12 cures mice infected with Leishmania major. Journal of Experimental Medicine, 177: 1505-1509. [ Links ]
34. Sypek JP, Chung CL, Mayor SEH, Subramanyan JM, Goldman SJ, Sieburgh DS, Wolf SF & Schaub RG (1993). Resolution of cutaneous leishmaniasis: IL-12 initiates a protective T helper type 1 immune response. Journal of Experimental Medicine, 177: 1797-1802. [ Links ]
35. Wang Z-E, Zheng S, Corry DB, Dalton DK, Seder RA, Reiner SL & Locksley RM (1994). Interferon gamma-independent effects of interleukin-12 administered during acute or established infection due to Leishmania major. Proceedings of the National Academy of Sciences, USA, 91: 12932-12936. [ Links ]
36. Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G & Scott P (1994). The adjuvant effect of IL-12 in a vaccine against Leishmania major. Science, 263: 235-237. [ Links ]
37. Ghalib HW, Whittle JA, Kubin M, Hashim FA, El-Hassan AM, Grabstein KH, Trinchieri G & Reed SG (1995). IL-12 enhances Th1-type responses in human Leishmania donovani infections. Journal of Immunology, 154: 4623-4629. [ Links ]
38. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman R, Johnson Jr WD & Carvalho EM (1996). Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. Journal of Infectious Diseases, 173: 1515-1518. [ Links ]
39. De Waal Malefyt R, Haanen J, Spits H, Roncarolo M-G, Te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H & De Vries JE (1991). Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. Journal of Experimental Medicine, 174: 915-924. [ Links ]
40. Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min H-Y & Lin L (1991). IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. Journal of Immunology, 148: 808-814. [ Links ]
41. Cunha FQ, Moncada S & Liew FY (1992). Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochemical and Biophysical Research Communications, 182: 1155-1159. [ Links ]
42. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW & O'Garra A (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. Journal of Immunology, 146: 3444-3451. [ Links ]
43. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M & O'Garra A (1991). IL-10 inhibits cytokine production by activated macrophages. Journal of Immunology, 147: 3815-3822. [ Links ]
44. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M & Trinchieri G (1993). Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. Journal of Experimental Medicine, 178: 1041-1048. [ Links ]
45. Cassatella MA, Meda L, Bonora S, Ceska M & Constantin G (1993). Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1b in mediating the production of IL-8 triggered by lipopolysaccharide. Journal of Experimental Medicine, 178: 2207-2211. [ Links ]
46. Nathan CF, Murray HW, Wiebe ME & Rubin BY (1983). Identification of interferon gamma as the lymphokine that activates human macrophages oxidative metabolism and antimicrobial activity. Journal of Experimental Medicine, 158: 670-689. [ Links ]
47. Murray HW, Rubin BY & Rothermel CD (1983). Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon gamma is the activating lymphokine. Journal of Clinical Investigation, 72: 1506-1510. [ Links ]
48. Murray HW, Berman JD & Wright SD (1988). Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. Journal of Infectious Diseases, 157: 973-978. [ Links ]
49. Carvalho EM, Badaro R, Reed SG, Jones TC & Johnson WD (1985). Absence of gamma interferon and interleukin-2 production during active visceral leishmaniasis. Journal of Clinical Investigation, 76: 2066-2069. [ Links ]
50. Carvalho EM, Bacellar O, Brownell CE, Regis T, Coffman RL & Reed SG (1994). Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. Journal of Immunology, 152: 5949-5956. [ Links ]
51. Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JLM, Reed SG & Rocha H (1985). Cell mediated immunity in American cutaneous and mucosal leishmaniasis. Journal of Immunology, 135: 4144-4148. [ Links ]
52. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, Carvalho JS, Barral-Netto M, Brandely M, Silva L, Bina JC, Teixeira R, Falcoff R, Rocha H, Ho JL & Johnson Jr WD (1990). Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New England Journal of Medicine, 322: 16-21. [ Links ]
53. Harms G, Chehadi AK, Racz P, Douba M, Naiff RD, Feldmeier H, Zwingenbuger K, Talhari S, Movakeh A, Nakel L, Kremsner PG & Bienzle V (1989). Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet, 10: 1287-1292. [ Links ]
54. Barral-Netto M, Barral A, Brodskyn C, Carvalho EM & Reed SG (1995). Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunology, 17: 21-28. [ Links ]
55. Wilson SM, Nava E, Morales A, Godfrey-Faussett P, Gillespie S & Andersson N (1993). Simplification of the polymerase chain reaction for detection of Mycobacterium tuberculosis in the tropics. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87: 177-180. [ Links ]
56. Brodskyn CL, Barral A, Boaventura V, Carvalho E & Barral-Netto M (1997). Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. Journal of Immunology, 159: 4467-4473. [ Links ]
Address for correspondence: M. Barral-Netto, Centro de Pesquisas Gonçalo Moniz, FIOCRUZ, Rua Waldemar Falcão, 121, Brotas, 40295-001 Salvador, BA, Brasil. Fax: 55 (071) 356-2255. E-mail: firstname.lastname@example.org
Presented at the International Meeting on Cytokines, Angra dos Reis, RJ, Brasil, November 24-28, 1996. Research supported by the NIH (TMRC No. AI 30639) and CNPq. M. Barral-Netto, E.M. Carvalho and A. Barral are Senior Investigators of CNPq. Received September 24, 1997. Accepted September 30, 1997.